Leinco Technologies

St. Louis, United States Founded: 1992 • Age: 34 yrs Acquired By Ampersand Capital
Manufacturer of antibodies, proteins, reagents, and kits for life science research
Annual revenue - Latest available
Total funding - 1 rounds
Employees - Tracked headcount
Investors 2 Known backers
Products 3 Services tracked
Competitors 11 Brand Intelligence

About Leinco Technologies

Leinco Technologies is a company based in St. Louis (United States) founded in 1992 was acquired by Ampersand Capital in November 2021. Leinco Technologies has completed 1 acquisition, including QED Bioscience. Leinco Technologies offers products and services including Antibodies, Proteins, and Custom Services. Leinco Technologies operates in a competitive market with competitors including GenScript, Sino Biological, Epitomics, Y-Biologics and Mabtech, among others.

  • Headquarter St. Louis, United States
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Leinco Technologies, Inc.
Operational Areas
Healthcare → Healthcare Services & Infrastructure Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    $1 M (USD), Grant

    Feb 06, 2025

  • Investors
  • Employee Count
    Not available
  • Investments & Acquisitions
  • Acquired by
    Ampersand Capital

    (Nov 17, 2021)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Leinco Technologies

Leinco Technologies offers a comprehensive portfolio of products and services, including Antibodies, Proteins, and Custom Services.

Product name locked
Category locked
Primary

High-quality antibodies for scientific and diagnostic applications

Product name locked
Category locked
Locked

Recombinant proteins supporting life sciences research studies

Product name locked
Category locked
Locked

Tailored antibody and protein production for research needs

People of Leinco Technologies

Headcount 10-50
Employee Profiles 4
Employee Profiles
People
Ryan Griffith
Director Of Sales
People
W. Pat Leinert Sr.
President and CEO
People
Michael J. Dishian
Chief Financial Officer

Unlock access to complete

Funding Insights of Leinco Technologies

Investors in Leinco Technologies

Leinco Technologies has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation and Ampersand Capital Partners.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Ampersand Capital Partners is focused on investments in healthcare and life sciences.
Locked Locked Locked
Charitable foundation investments on poverty reduction and healthcare
Locked Locked Locked
Premium access

Investor details for Leinco Technologies

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Leinco Technologies

Leinco Technologies has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include QED Bioscience.

Investments
Premium access

Investment portfolio details for Leinco Technologies

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Acquisitions
Company Name Description Domain Location Founded Year Amount
Proteins and antibody reagents for research
Locked Locked 1997 Locked
Premium access

Complete acquisition details for Leinco Technologies

Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.

  • Transaction dates
  • Acquired stakes
  • Disclosed values
  • Domains and locations

Verified entity values are shown only after access is granted.

Financial Statements - Leinco Technologies

Premium access

Detailed financials for Leinco Technologies

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Leinco Technologies Comparisons

Leinco Technologies Primary company
Description
Manufacturer of antibodies, proteins, reagents, and kits for...
Location
St. Louis, United States
Founded Year
1992
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Leinco Technologies

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Leinco Technologies

Leinco Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GenScript, Sino Biological, Epitomics, Y-Biologics and Mabtech, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Reagents and instruments are provided for life sciences research.
Locked Locked Locked
Reagents and kits are provided for clinical research applications.
Locked Locked Locked
Monoclonal antibody technology and products are developed by Epitomics.
Locked Locked Locked
Developer of antibodies for the treatment of multiple diseases
Locked Locked Locked
Antibodies and immunoassay kits are developed for research applications.
Locked Locked Locked
Antibody and vaccine culture media products are developed.
Premium access

Detailed competitors of Leinco Technologies

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Leinco Technologies

Premium access

Complete news archive for Leinco Technologies

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Leinco Technologies

Leinco Technologies was founded in 1992 and raised its 1st funding round 33 years after it was founded.

Leinco Technologies is headquartered in St. Louis, United States. It is registered at St. Louis, Missouri, United States.

Leinco Technologies was founded in 1992 in St. Louis, United States, and operates within the life science research sector. Antibodies, proteins, in vitro diagnostic products, buffers, and reagents are produced and supplied, organized by research area, application, and antigen. Custom services are offered, including antibody development, cell line creation, protein production, lyophilization, and conjugation processes.

Leinco Technologies's top competitors include Sino Biological, GenScript and Y-Biologics.

Leinco Technologies offers Antibodies, Proteins, and Custom Services.

Leinco Technologies has made 1 acquisition, including QED Bioscience.

Leinco Technologies has 2 investors. Key investors include Gates Foundation, and Ampersand Capital Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available